Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene, located on the X chromosome at position Xp21.2. These mutations prevent the body from producing a functional version of a protein called dystrophin, which muscles need to survive the normal stress of contraction. Without it, muscle fibers progressively break down and are replaced by scar tissue and fat, leading to severe weakness that typically becomes apparent between ages 3 and 5.
The Role of Dystrophin in Healthy Muscle
Dystrophin is a rod-shaped protein that acts as a structural anchor inside muscle cells. It sits just beneath the cell membrane and connects the internal scaffolding of the cell (the cytoskeleton) to the protective matrix surrounding it. Think of it as a shock absorber: every time a muscle contracts, the membrane experiences mechanical stress, and dystrophin helps distribute that force so the membrane stays intact.
It does this by binding directly to a network of structural fibers inside the cell on one end, and to a cluster of proteins embedded in the cell membrane on the other. That cluster, called the dystrophin-associated protein complex, reaches through the membrane and links to the connective tissue outside the cell. The result is a continuous chain from the inside of the muscle fiber to the outside, keeping everything stable during movement. When dystrophin is missing, this entire chain falls apart.
What Goes Wrong at the Cellular Level
Without dystrophin anchoring the membrane complex in place, the muscle cell membrane becomes fragile. During normal contractions, it develops small tears. These tears allow calcium to flood into the cell from outside, and they also trigger abnormal calcium release from internal storage sites. Calcium normally acts as a signaling molecule inside cells, but in excessive amounts it becomes destructive, activating inflammatory pathways and enzymes that damage the cell from within.
The calcium overload in DMD is not just a one-time event. It becomes a self-reinforcing cycle: membrane damage lets calcium in, calcium triggers inflammation, inflammation causes further membrane damage. Internal calcium pumps that would normally restore balance work more slowly in dystrophic muscle, so the excess calcium lingers. Over time, the sustained calcium elevation makes the cell’s internal environment toxic enough that the muscle fiber dies.
Muscle tissue has limited ability to regenerate. In DMD, the constant cycle of damage outpaces the body’s ability to grow new muscle fibers. The body fills in the gaps with fibrous scar tissue first, then fatty tissue later. This is why affected muscles can actually appear larger in early stages (a phenomenon called pseudohypertrophy, commonly seen in the calves) even as they’re getting weaker. The bulk comes from fat and connective tissue, not functional muscle.
Types of Mutations That Cause DMD
The dystrophin gene is one of the largest in the human genome, spanning about 2.4 million base pairs. Its sheer size makes it unusually vulnerable to genetic errors. In a study of 250 DMD patients, the breakdown of mutation types was:
- Large deletions: 63% of cases, where one or more sections of the gene are missing entirely
- Duplications: about 25%, where sections of the gene are copied an extra time
- Point mutations: roughly 6%, involving changes to individual letters of the genetic code
- Other small mutations: the remaining cases, including small insertions, deletions, or missense changes
The type of mutation matters for treatment planning, but all of them share the same downstream effect: the cell either produces no dystrophin at all or produces a version so truncated that it can’t function. This distinguishes Duchenne from the milder Becker muscular dystrophy, where mutations allow a partially functional (though shorter) dystrophin protein to be made.
How DMD Is Inherited
DMD follows an X-linked recessive inheritance pattern. Because males have only one X chromosome, a single defective copy of the dystrophin gene is enough to cause the disease. Females have two X chromosomes, so a working copy on the second X typically compensates. This is why DMD overwhelmingly affects boys, occurring in roughly 20 per 100,000 live male births worldwide.
A woman who carries one mutated copy is called a carrier. If she has a son, there’s a 50% chance he’ll inherit the affected X chromosome and develop DMD. If she has a daughter, there’s a 50% chance the daughter will be a carrier. Most female carriers have no obvious muscle symptoms, though up to 20% experience mild to moderate weakness and about 50 to 60% show elevated levels of creatine kinase (a blood marker of muscle damage). Carriers also face an estimated 17% lifetime risk of developing heart problems related to the mutation, even without skeletal muscle symptoms.
Not every case is inherited from a carrier mother. About one-third of DMD cases arise from new (de novo) mutations, meaning the genetic change happened spontaneously either in the egg, during early development, or through a phenomenon called germline mosaicism, where a parent carries the mutation in some of their reproductive cells but not in their blood cells. This is why DMD can appear in families with no prior history of the disease.
How the Cause Is Confirmed
The first clue is often a blood test showing extremely high creatine kinase levels. In boys with DMD, these levels can reach 10 to 20 times the upper limit of normal by age 2, sometimes even before any visible symptoms appear. Elevated CK signals that muscle cells are breaking down and leaking their contents into the bloodstream, but it doesn’t identify the specific genetic cause.
Genetic testing is the definitive step. The standard first-line test looks for large deletions and duplications in the dystrophin gene, which together account for nearly 90% of cases. If that test comes back negative, targeted sequencing of the entire gene can pick up the smaller point mutations and single-letter changes that the initial screen misses. In clinical studies, this two-step approach identifies the causative mutation in virtually all confirmed DMD cases. Pinpointing the exact mutation is important not only for diagnosis but also for determining eligibility for mutation-specific therapies, such as exon-skipping treatments designed for particular deletion patterns.